Ipsen, Boiron, Daiichi-Sankyo, Recordati in brief

1 August 2018 - Deborah Wilkes

Ipsen Consumer Healthcare, Boiron, Daiichi-Sankyo's OTC business and Recordati have just released financial results.

Ipsen highlights Smecta performance

Sales by Ipsen's Consumer Healthcare business fell by 3.9% at constant exchange rates to EUR144 million (USD167 million) in the first half of 2018. As reported, the fall was 6.8% compared to the first half of 2017.

The French pharmaceutical company said the performance had been impacted by a new contractual set up in China for Etiasa. Excluding Etiasa, sales would have been up by 2.0%.

Ipsen highlighted the "good performance" of the antidiarrhoeal Smecta, which was the largest Consumer Healthcare product with sales up by 3.6% at constant currencies to EUR62.4 million.

Core operating income at the Consumer Healthcare business was EUR41.8 million in the first half of 2018, giving a core operating margin of 29.0%.

The Consumer Healthcare business generated 13.6% of Ipsen's total sales in the first half of 2018, which were up by 21.5% at constant exchange rates to EUR1.06 billion.

Boiron sees small increase

Boiron reported worldwide sales of EUR281 million (USD326 million) in the first half of 2018, representing a rise of 0.9% at constant exchange rates compared to the same period a year earlier. As reported, sales were down by 1.5%.

The majority of sales, 60.3%, were generated in the homoeopathy specialist's home market of France, where sales dropped by 4.1% to EUR169 million.

Boiron's sales in Europe, excluding France, were down by 13.1% at constant exchange rates to EUR57.7 million, while sales in North America rose by 51.8% to EUR44.6 million. Sales in other countries were up by 24.8% at constant exchange rates to EUR9.1 million.

Daiichi-Sankyo sees OTC rise in Japan

Sales by Daiichi-Sankyo's OTC business in Japan grew by 9.1% to JPY18.4 billion (USD0.17 billion) in the three months ended 30 June 2018. The Japanese pharmaceutical company highlighted growth of the Minon brand.

The Japanese OTC business accounted for 8% of Daiichi-Sankyo's total sales, which decreased by 5.6% to JPY226 billion.

Recordati reports 6.9% rise

Recordati reported sales of EUR696 million (USD808 million) in the first half of 2018, representing a rise of 6.9% compared to the same period a year earlier. Around 80% of Recordati's sales were generated outside the Italian pharmaceutical company's home market.

The OTC business accounted for 15.5% of Recordati's worldwide sales.

Recordati's operating income grew by 14.1% to EUR232 million, representing 33.3% of sales. Earnings Before Interest, Taxes, Depreciation and Amortisation (EBITDA) were up by 16.1% to EUR260 million, representing 37.4% of sales.

The family-owned company recently announced that a consortium led by private-equity firm CVC Capital Partners was acquiring a majority stake in Recordati for EUR3.03 billion (click here to read the News story).

Take out an Annual Subscription to the OTCToolbox website, giving you UNLIMITED ACCESS to all of our publications
* Premium News Stories
* OTCToolbox Innovations magazine NEW IDEAS BETTER WAYS
* OTCToolbox Deals Database
* News Extras
* OTC Deal Trends Briefing
* OTC Company Strategies Report
Helping you and your company make well-informed decisions
CLICK HERE TO FIND OUT MORE

Click tags below for more information on topics:

Ipsen Boiron Homeopathy Daiichi Sankyo Recordati

Back to Industry News

Share this page: